A clinical study assessing the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the combination therapy using sintilimab and NEO_PLIN2101 from in cancer patients.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs NEO-PLIN2101 (Primary) ; Sintilimab (Primary)
Indications Cancer
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

02 Nov 2021 New trial record
27 Oct 2021 According to an Innovent Biologics media release, company prepare to submit the Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) in the near future.
27 Oct 2021 According to an Innovent Biologics media release, Innovent Biologics and NeoCura jointly announced that they have entered into a strategic collaboration agreement to carry out this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com